Download PDF
Thromb Haemost 1995; 74(05): 1353-1360
DOI: 10.1055/s-0038-1649939
Original Article
Animal Models
Schattauer GmbH Stuttgart

Inhibition of Arterial Thrombus Formation in Two Canine Models: Comparison of Ancrod, a Fibrinogen-Depleting Agent, the Thrombin-Inhibitor r-Hirudin, and the Glycoprotein IIb/IIIa-Receptor Antagonist Ro 43-8857

K Rübsamen
Knoll AG, Research and Development, Preclinical Anglology, Germany
,
W Hornberger
*   Preclinical Cardiology, Ludwlgshafen, Germany
,
M Kirchengast
Knoll AG, Research and Development, Preclinical Anglology, Germany
› Author Affiliations
Further Information

Publication History

Received 06 January 1995

Accepted after revision 04 August 1995

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Inhibition of arterial thrombus formation by ancrod, a fibrinogen depleting agent isolated from a snake venom, r-hirudin, an inhibitor of thrombin-mediated fibrinogen cleavage, or the glycoprotein (GP)IIb/IIIa-receptor antagonist Ro 43-8857 interfering with fibrinogen binding to platelets, was evaluated in two canine models. As a marker of platelet-dependent thrombus formation, cyclic blood flow reductions (CFR) were induced in the left coronary artery (LAD) of mongrel dogs by mechanical injury of the endothelium combined with critical stenosis. In the second model CFRs were induced by thrombolysis of a copper coil-induced thrombus in the carotid artery. Blood flow rate during the reocclusion phase was used as an additional parameter of efficacy.

The frequency of CFRs used as indicator of platelet aggregation and adhesion was significantly diminished by all treatments in both the carotid artery- and the LAD-model. In the LAD-model, following ancrod treatment, CFRs were correlated with plasma fibrinogen concentrations. Carotid artery blood flow after reperfusion, used as indicator of occlusive thrombus formation, rapidly declined to zero in the control group but remained at a high level after treatment with ancrod or r-hirudin. Ro 43-8857 at the selected dose improved blood flow rate only to a minor degree but prolonged the bleeding time from a mean value of 87.2 ± 10.9 s (n = 24) to values >300 s in 50% of the animals.

Our results indicate that CFRs as indicator of platelet aggregation and adhesion are inhibited by either treatments. Blood flow as indicator of occlusive thrombus formation, however, is effectively improved by ancrod and r-hirudin only. Inhibition of fibrinogen binding to platelet GPIIb/IIIa receptors alone was found to be a less potent antithrombotic principle in this model.

 

  • References

  • 1 Chesebro JH, Badimon L, Fuster V. New approaches to treatment of myocardial infarction. Am J Cardiol 1990; 65: 12C-19C
    CrossrefPubMedGoogle Scholar
  • 2 Yasuda T, Gold H, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanka M, Shealy D, Ross MJ, Collen D, Coller BS. Monoclonal antibody against the platelet glycoprotein (GP) Ilb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284-1291
    CrossrefPubMedGoogle Scholar
  • 3 Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein Ilb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-722
    CrossrefPubMedGoogle Scholar
  • 4 Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370
    CrossrefPubMedGoogle Scholar
  • 5 Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation,and blockade of GPIIb/IIIa receptors Circulation 1989; 80: 176674
    PubMedGoogle Scholar
  • 6 Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen J. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 1989; 74: 1025-1030
    PubMedGoogle Scholar
  • 7 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin IlI-independent inhibitors. J Clin Invest 1990; 86: 385-391
    CrossrefPubMedGoogle Scholar
  • 8 Esnouf MP, Tunnah GW. The isolation and properties of the thrombin-like activity from Ancistrodon rhodostoma venom. Brit J Haemat 1968; 15: 589-602
    CrossrefPubMedGoogle Scholar
  • 9 Bell WR, Bolton G, Pitney WR. The effect of arvin on blood coagulation factors. Brit J Haemat 1968; 15: 589-602
    CrossrefPubMedGoogle Scholar
  • 10 Edgar W, Prentice CR M. The proteolytic action of ancrod on human fibrinogen and its polypeptide chains. Thromb Res 1973; 2: 85-96
    CrossrefPubMedGoogle Scholar
  • 11 Brown CH, Bell WR, Shreiner DP, Jackson DP. Effect of arvin on blood platelets In vitro and in vivo studies. J Lab Clin Med 1972; 79: 758-769
    PubMedGoogle Scholar
  • 12 Kordenat RK, Kezdi P, Stanley EL. A new catheter technique for producing experimental coronary thrombosis and selective coronary visualization. Amer Heart J 1972; 83: 360-364
    CrossrefPubMedGoogle Scholar
  • 13 Brassard JA, Meyers KM. Evaluation of the buccal bleeding time and platelet glass bead retention as assays of hemostasis in the dog: The effects of acetylsalicylic acid, warfarin and von Willebrand factor deficiency. Thromb Haemost 1991; 65: 191-195
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Clauss A. Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol 1957; 17: 237-239
    CrossrefPubMedGoogle Scholar
  • 15 Alig L, Edenhofer A, Hadvary P, Hiirzeler M, Knopp D, Muller M, Steiner B, Trzeciak A, Weller T. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35: 4393-4407
    CrossrefPubMedGoogle Scholar
  • 16 Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83 Suppl (Suppl. 04) IV-3-IV-14
    PubMedGoogle Scholar
  • 17 Cerek B, Lew AS, Hod H, Yano J, Lewis B, Reddy KN N, Ganz W. Ancrod enhances the thrombolytic effect of streptokinase and urokinase. Thromb Res 1987; 47: 417-426
    CrossrefPubMedGoogle Scholar
  • 18 Tomaru T, Uchida Y, Nakamura F, Sonoki H, Tsukamoto M, Sugimoto T. Enhancement of arterial thrombolysis with native tissue-type plasminogen activator by pretreatment with heparin or batroxobin: An angioscopic study. Am Heart J 1989; 117: 275-281
    CrossrefPubMedGoogle Scholar
  • 19 Apprill PG, Ashton J, Guerrero J, Glas-Greenwalt P, Buja LM, Willerson JT. Ancrod decreases the frequency of cyclic flow variations and causes thrombolysis following acute coronary thrombosis. Am Heart J 1987; 113: 898-906
    CrossrefPubMedGoogle Scholar
  • 20 Rapold HJ, Gold HK, Wu Z, Napier M, Bunting S, Collen D. Effects of G4120, a ARG-GLY-ASP containing synthetic platelet glycoprotein Ilb/IIIa receptor antagonist, on arterial and venous thrombolysis with recombinant tissue-type plasminogen activator in dogs. Fibrinolysis 1993; 7: 248-56
    PubMedGoogle Scholar
  • 21 Rote WE, Wems SW, Davis JH, Feigen LP, Kilgore KS, Lucchesi BR. Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery. Cardiovasc Res 1993; 27: 500-507
    CrossrefPubMedGoogle Scholar
  • 22 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056
    CrossrefPubMedGoogle Scholar
  • 23 Cook NS, Bruttger O, Pally C, Hagenbach A. The effects of two synthetic glycoprotein Ilb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: Evidence that Ro 438857 is orally active. Thromb Haemost 1993; 70: 838-847
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab’)2fragment J Cardiovasc Pharmacol 1994; 23: 194-202
    CrossrefPubMedGoogle Scholar
  • 25 Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin J Cardiovasc Pharmacol 1994; 23: 203-211
    CrossrefPubMedGoogle Scholar
  • 26 Heras M, Chesebro JH, Webster MW I, Mruk JS, Grill DE, Penny WJ, Bowie EJ W, Badimon L, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet- mediated thrombosis Circulation 1990; 82: 1476-1484
    CrossrefPubMedGoogle Scholar
  • 27 Yao SK, McNatt J, Anderson HV, Eidt J, Cui K, Golino P, Glas-Greenwalt P, Maraganore J, Buja LM, Willerson JT. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. Am J Physiol 1992; 262: H374-H379
    CrossrefPubMedGoogle Scholar
  • 28 Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circulation Res 1993; 72: 1091-1102
    CrossrefPubMedGoogle Scholar
  • 29 Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J ACC 1993; 22: 296-301
    PubMedGoogle Scholar
  • 30 Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994; 89: 1802-1809
    CrossrefPubMedGoogle Scholar
  • 31 Kirchengast M, Münter K, Rübsamen K. The Ca2+antagonist verapamil potentiates the effect of the ACE-inhibitor trandolapril on cyclic coronary blood flow reductions. J Vase Med Biol 1994; 5: 144-151
    PubMedGoogle Scholar
  • 32 The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994; 25: 1755-1759
    CrossrefPubMedGoogle Scholar
  • 33 Garabedian HK, Gold HK, Leinbach RC, Yasuda T, Johns JA, Thornton D, Collen D. Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. Thromb Res 1988; 50: 121-133
    CrossrefPubMedGoogle Scholar